The periorbital region is at the pinnacle of conferring youth and vitality to the face. Facial lines, furrows, and hollows can signify fatigue and aging, while smooth skin and convexities convey a cherubic, youthful impression. Surgical rejuvenation of the periorbital region continues to play a large role in achieving the latter. However, in patients with hyperfunctional lines and tear trough or other contour deformities, neurodmodulators and injectable soft-tissue fillers play a substantial, growing role in their treatment. With the advent of newer technology, the armamentarium of products available to cosmetic surgeons continues to expand. Keeping abreast of these products, their indications and nuances are paramount to achieving a safe and successful result.
Cervical Dystonia Frontalis Muscle Orbital Septum Corrugator Supercilii Periorbital Region
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8 Suppl 5:21.CrossRefGoogle Scholar
Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 2001;39:1815.CrossRefGoogle Scholar
Carruthers J, Glogau RG, Blitzer A. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies – consensus recommendations. Plast Reconstr Surg. 2008;121(Suppl):5S–30.CrossRefGoogle Scholar
Ramirez AL, Reeck J, Maas CS. Botulinum toxin type (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002;126(5):459–67.CrossRefGoogle Scholar
Ramirez AL, Reeck J, Maas CS. Preliminary experience with botulinum toxin type B in hyperkinetic facial lines. Plast Reconstr Surg. 2002;109(6):2154–5.CrossRefGoogle Scholar
Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am. 2007;15:63–76.CrossRefGoogle Scholar
Lowe NJ, Maxwell A, Lowe P, et al. Hyaluronic acid fillers: adverse reactions and skin testing. J Am Acad Dermatol. 2001;45:930–3.CrossRefGoogle Scholar
Micheels P. Human antihyaluronic acid antibodies: is it possible? Dermatol Surg. 2001;27:185–91.PubMedGoogle Scholar
Maas CS, Yu K, Egan KK. Neuromodulators and injectable soft tissue substitutes. In: Papel I, editor. Facial plastic and reconstructive surgery. New York: Thieme; 2009. p. 346.Google Scholar
Ahn M, Catten M, Maas CS. Temporal browlift using botulinum toxin. Plast Reconstr Surg. 2000;105:1129–35.CrossRefGoogle Scholar
Maas CS, Kim EJ. Temporal browlift using botulinum toxin A: an update. Plast Reconstr Surg. 2003;112 Suppl 5:109S–12.CrossRefGoogle Scholar
Macdonald MR, Spiegel JH, Raven RB, et al. An anatomical approach to glabellar rhytids. Arch Otolaryngol Head Neck Surg. 1998;124:1315–20.CrossRefGoogle Scholar
Northington ME, Huang CC. Dry eyes and superficial punctate keratitis: a complication of treatment of glabelar dynamic rhytides with botulinum exotoxin A. Dermatol Surg. 2004;30:1515–7.PubMedGoogle Scholar
Aristodemou P, Watt L, Baldwin C, et al. Diplopia associated with the cosmetic use of botulinum toxin A for facial rejuvenation. Ophthal Plast Reconstr Surg. 2006;22:134–6.CrossRefGoogle Scholar